225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience
Sign Up to like & getrecommendations! Published in 2019 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-019-04612-0
Abstract: Up to 30% of patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) never respond or develop resistance to 177Lu-labeled PSMA-targeted radioligand monotherapy. Single-agent PSMA-targeted radioligand therapy (PRLT) with the alpha-emitter 225Ac showed… read more here.
Keywords: psma 617; 177lu psma; 225ac psma; tandem therapy ... See more keywords
Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-022-05778-w
Abstract: Actinium-225-labeled prostate-specific membrane antigen ([225Ac]Ac-PSMA-617) is safe and effective in the treatment of metastatic castration-resistant prostate cancer (mCRPC). No study has specifically assessed its safety in patients with extensive skeletal metastases of mCRPC. We aimed… read more here.
Keywords: toxicity; hematologic toxicity; treatment; skeletal metastases ... See more keywords
Therapeutic efficacy of 225Ac-PSMA-617 targeted alpha therapy in patients of metastatic castrate resistant prostate cancer after taxane-based chemotherapy
Sign Up to like & getrecommendations! Published in 2021 at "Annals of Nuclear Medicine"
DOI: 10.1007/s12149-021-01617-4
Abstract: 225Ac-PSMA-617 therapy has shown good response in many recent studies. We report our experience of targeted alpha therapy with 225Ac-PSMA-617 in mCRPC patients who have failed therapy with taxanes. Thirty-eight patients with CRPC with progressive… read more here.
Keywords: psma 617; taxane based; based chemotherapy; 225ac psma ... See more keywords
Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer-a systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2021 at "Prostate cancer and prostatic diseases"
DOI: 10.1038/s41391-021-00349-w
Abstract: BACKGROUND Targeted radionuclide therapy with Actinium-225-labeled prostate-specific membrane antigen ligands (225Ac-PSMA) has emerged as a promising treatment modality in the management of metastatic castration-resistant prostate cancer (mCRPC). With its high linear energy transfer and short… read more here.
Keywords: therapy; systematic review; prostate cancer; 225ac psma ... See more keywords
225Ac-PSMA-617 for Therapy of Prostate Cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Seminars in nuclear medicine"
DOI: 10.1053/j.semnuclmed.2020.02.004
Abstract: Prostate-specific membrane antigen (PSMA)-targeting radio-ligand therapy with beta-emitting 177Lutetium has already been investigated in several early phase dosimetry studies, demonstrated promising results in phase-2, and recently the first phase-3 trial finished recruitment. In contrast, PSMA-targeting… read more here.
Keywords: prostate; therapy; psma 617; 225ac psma ... See more keywords
mCRPC Patients Receiving 225Ac-PSMA-617 Therapy in the Post–Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Nuclear Medicine"
DOI: 10.2967/jnumed.121.263618
Abstract: Visual Abstract 225Ac-PSMA-617, targeting the prostate-specific membrane antigen (PSMA), which is overexpressed on prostate cancer cells, has shown a remarkable therapeutic efficacy in heavily pretreated patients with metastatic castration-resistant prostate carcinoma (mCRPC). Here, we report… read more here.
Keywords: psma 617; 225ac psma; psa decline; patients psa ... See more keywords
[225Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [225Ac]Ac-PSMA-617
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14225651
Abstract: Simple Summary Prostate-specific membrane antigen (PSMA) radioligands have proven effective to treat patients with metastatic castration-resistant prostate cancer. Targeted α-therapy using actinium-225 has been used for patients with end-stage disease who no longer responded to… read more here.
Keywords: psma 617; 225ac sibudab; therapy; psma ... See more keywords
Advances in 177Lu-PSMA and 225Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics14102166
Abstract: For patients with metastatic castration-resistant prostate cancer (mCRPC), the survival benefit of classic treatment options with chemotherapy and drugs targeting androgen signaling is limited. Therefore, beta and alpha radionuclide therapy (RNT) have emerged as novel… read more here.
Keywords: psma 225ac; prostate cancer; 177lu psma; psma ... See more keywords
Relative Efficacy of 225Ac-PSMA-617 and 177Lu-PSMA-617 in Prostate Cancer Based on Subcellular Dosimetry
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Imaging and Radionuclide Therapy"
DOI: 10.4274/mirt.galenos.2021.63308
Abstract: Objectives: Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) with alpha-emitting 225Ac-PSMA-617 has shown clinical efficacy even in cases of failed therapy with beta-emitting 177Lu-PSMA-617. We investigated the efficacy of 225Ac-PSMA-617 relative to 177Lu-PSMA-617 using subcellular… read more here.
Keywords: psma 617; 177lu psma; efficacy 225ac; psma ... See more keywords